Sugi Predict

Sugi Predict / Compounds / SCHEMBL148956

SCHEMBL148956

SCHEMBL148956

O=C(NC1CC1)c1cccc(B(O)O)c1

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 5/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ SMYD3 Q9H7B4 5/20 0.55
▸ RAB9A P51151 4/20 0.54
▸ GRM5 P41594 2/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ GFER P55789 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ PKM P14618 1/20 0.50
▸ KDM1A O60341 1/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ HTT P42858 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29953351 0.94 NPC1 (0.51) NPC1L3MBTL1SMYD3RAB9AGRM5
SCHEMBL3040194 0.94 L3MBTL1 (0.64) NPC1L3MBTL1RAB9AGRM5SMN1; SMN2
SCHEMBL15535810 0.92 RAB9A (0.65) NPC1L3MBTL1RAB9AGRM5SMN1; SMN2
SCHEMBL18579817 0.87 KMT2A (0.50) NPC1L3MBTL1SMYD3RAB9AMEN1
SCHEMBL21953980 0.84 KDM1A (0.51) NPC1L3MBTL1RAB9AGRM5KDM1A
SCHEMBL2559523 0.84 HRH3 (0.54) NPC1RAB9AMEN1KMT2A
SCHEMBL7305442 0.83 NPC1 (0.46) NPC1L3MBTL1SMYD3RAB9ASMN1; SMN2
SCHEMBL1116603 0.80 GRM5 (0.77) NPC1L3MBTL1SMYD3RAB9AGRM5
SCHEMBL119671 0.80 RAB9A (0.59) NPC1SMYD3RAB9ASMN1; SMN2MEN1
SCHEMBL3184904 0.80 NPC1 (0.67) NPC1L3MBTL1SMYD3RAB9AGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 — — US disclosed
WO-2024191268-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 현대약품 주식회사 2024-09-19 — — WO disclosed
CN-117343081-A MAT2A inhibitor, pharmaceutical composition and application thereof 南京正大天晴制药有限公司 2024-01-05 — — CN disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
US-11572337-B2 Antibacterial agents: arylalkylcarboxamido phloroglucinols RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2023-02-07 — — US disclosed
US-20230012449-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2023-01-12 — — US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 — — US disclosed
US-11034668-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2021-06-15 — — US disclosed
US-20210017126-A1 Antibacterial Agents: Arylalkylcarboxamido Phloroglucinols RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2021-01-21 — — US disclosed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 — — US disclosed
WO-2008054956-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2008-05-08 — — WO disclosed
WO-2008045834-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2008-04-17 — — WO disclosed
WO-2008045834-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2008-04-17 — — WO disclosed
US-20070259907-A1 ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2007-11-08 — — US disclosed
EP-1812439-A2 KINASE INHIBITORS Takeda San Diego, Inc. (US) 2007-08-01 — — EP disclosed
US-20070117816-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-24 — — US disclosed
WO-2007044779-A1 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2007-04-19 — — WO disclosed
WO-2006093514-A2 ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-09-08 — — WO disclosed
WO-2006044687-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2006-04-27 — — WO disclosed
US-20060084650-A1 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084650-A1 Kinase inhibitors MAP3K20, MAP3K19, MAP3K1 NPC1 4032/4885L3MBTL1 4518/4885SMYD3 2524/4885
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB NPC1 1419/4885L3MBTL1 3069/4885SMYD3 3834/4885
US-11572337-B2 Antibacterial agents: arylalkylcarboxamido phloroglucinols RNGTT, FBL, POLR1C NPC1 2370/4885L3MBTL1 3209/4885SMYD3 2140/4885
US-20070259907-A1 ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES IL2, TSLP, IFNG NPC1 1672/4885L3MBTL1 2951/4885SMYD3 4431/4885
US-20070117816-A1 KINASE INHIBITORS MAP3K20, MAP3K19, MAP3K1 NPC1 3980/4885L3MBTL1 4528/4885SMYD3 2548/4885
US-11034668-B2 Compounds for the treatment of HIV CCR5, NPC1, FURIN NPC1 2/4885L3MBTL1 4307/4885SMYD3 1524/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB NPC1 1419/4885L3MBTL1 3069/4885SMYD3 3834/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A NPC1 2061/4885L3MBTL1 3936/4885SMYD3 4438/4885
US-20210017126-A1 Antibacterial Agents: Arylalkylcarboxamido Phloroglucinols RNGTT, FBL, POLR1C NPC1 2370/4885L3MBTL1 3209/4885SMYD3 2140/4885
US-20230012449-A1 COMPOUNDS FOR THE TREATMENT OF HIV CCR5, NPC1, FURIN NPC1 2/4885L3MBTL1 4307/4885SMYD3 1524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.